Search clinical trials for: Romosozumab

Total 37 results

Amgen

Recruiting

A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.

Postmenopausal Osteoporosis

India
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis

Multiple Myeloma | Osteoporosis

United States
UCB Biopharma SRL

Completed

A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

Osteoporosis

China
Amgen
UCB Pharma

Completed

Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing (STARTT)

Fracture Healing

Canada, Italy, United States, Russian Federation, France, Germany, Hong Kong, Hungary, Australia, Bulgaria, Poland, Romania, Greece, Denmark, Estonia, India, New Zealand, United Kingdom, Latvia, Slovakia, Lithuania, Mexico, Norway
Amgen

Completed

A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis

Postmenopausal Osteoporosis

Korea, Republic of
Amgen

Completed

Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

Osteoporosis

United States
Amgen

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)

Osteopenia | Postmenopausal
Amgen

Completed

A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass

Osteopenia
Amgen

Completed

A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis (BRIDGE)

Osteoporosis in Men

United States, Belgium, Colombia, Czechia, Denmark, Japan, Mexico, Poland, Russian Federation, Switzerland
Amgen

Completed

A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women

Osteopenia
Amgen

Completed

A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women

Osteopenia
Amgen

Completed

Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis

Postmenopausal Osteoporosis (PMO)

Japan
Tuen Mun Hospital

Completed

Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users

Glucocorticoid-induced Osteoporosis

China
Amgen

Completed

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

Post-Menopausal Osteoporosis

United States, Poland, United Kingdom
Amgen

Completed

Study To Assess FRacTure Healing With SclerosTin Antibody - Hip (STARTT-Hip)

Fracture Healing

Finland, Italy, Sweden, United States, Belgium, Switzerland, Canada, Hong Kong, Hungary, Germany, Netherlands, Bulgaria, Australia, Poland, Greece, Denmark, United Kingdom, Estonia, India, New Zealand, Latvia, Lithuania, Argentina, Sl...
Amgen

Completed

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis (ARCH)

Postmenopausal Women With Osteoporosis

United States, Canada, Denmark, France, Germany, Italy, Belgium, Colombia, Czechia, Mexico, Poland, Russian Federation, Netherlands, Hungary, Peru, Turkey, Taiwan, Spain, Hong Kong, Austria, Slovakia, United Kingdom, South Africa, Aus... and more
Amgen

Completed

Transition From Alendronate to Romosozumab (AMG 785)

Osteoporosis

United States
Amgen

Completed

A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis

Postmenopausal Osteoporosis

United States, Poland, Czechia
Sheba Medical Center

Not yet recruiting

Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density

Spinal Cord Injuries | Osteoporosis Fracture
University of Missouri-Columbia

Completed

Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome (NEOSURF)

Respiratory Distress Syndrome

United States
Northwestern University
Amgen

Active, not recruiting

Romosozumab in Women With Chronic SCI

Osteoporosis | Bone Loss | Spinal Cord Injuries | Osteopenia, Osteoporosis | Chronic Spinal Paralysis

United States
Massachusetts General Hospital

Active, not recruiting

Anabolic Therapy in Postmenopausal Osteoporosis

Postmenopausal Osteoporosis

United States
James J. Peters Veterans Affairs Medical Center
Kessler Institute for Rehabilitation

Active, not recruiting

Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI

Osteoporosis | Spinal Cord Injuries

United States
Amgen

Recruiting

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

Osteogenesis Imperfecta

Turkey, Hungary, Switzerland, Spain, Japan, France, Belgium, Poland, Australia, Austria, Slovakia, United States, Canada
Amgen

Completed

Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis (FRAME)

Postmenopausal Osteoporosis

United States, Canada, Denmark, Germany, Belgium, Colombia, Czechia, Japan, Mexico, Poland, Switzerland, Hungary, Spain, Australia, Romania, United Kingdom, India, Argentina, Brazil, Dominican Republic, Estonia, Latvia, Lithuania, New...
Karen Klahr Miller, MD
Amgen

Active, not recruiting

Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa

Anorexia Nervosa | Bone Loss | Eating Disorders | Bone Density, Low

United States
Amgen

Completed

Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density

Postmenopausal Osteoporosis | Low Bone Mineral Density
University of Aarhus

Recruiting

The Optimised Use of Romozosumab Study (OPTIMIST)

Osteoporosis

Denmark
James J. Peters Veterans Affairs Medical Center
Kessler Institute for Rehabilitation

Recruiting

Treatment With Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

Osteoporosis | Spinal Cord Injuries

United States
Amgen

Completed

Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta

Osteogenesis Imperfecta

Spain, United States, Turkey, Austria, Germany, Greece, Hungary, Italy
Columbia University
Amgen

Recruiting

Romosozumab/Denosumab Study for Premenopausal IOP

Premenopausal Idiopathic Osteoporosis

United States
VA Office of Research and Development
Kessler Institute for Rehabilitation

Active, not recruiting

Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI (Chronic Romo)

Spinal Cord Injury (=3 Years) | Sublesional Bone Loss Secondary to SCI

United States
424 General Military Hospital

Recruiting

Sequential Therapies After Osteoanabolic Treatment (START)

Osteoporosis, Postmenopausal

Greece, Germany, Italy
Amgen

Completed

An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women (STRUCTURE)

Postmenopausal Osteoporosis

Canada, Belgium, United States, Czechia, Denmark, Poland, Hungary, Spain, Colombia, United Kingdom, Argentina
Susan L. Greenspan
National Institutes of Health (NIH); National Institute on Aging (NIA)

Recruiting

Romosozumab Use to Build Skeletal Integrity (RUBI)

Osteoporosis | Osteoporosis, Postmenopausal | Osteoporosis Fracture

United States
Catholic University of the Sacred Heart
Monash University; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) and other collaborators

Completed

Efficacy of a New Technique -"IN-REC-SUR-E"- in Preterm Neonates With RDS

Respiratory Distress Syndrome | Hyaline Membrane Disease

Italy
Gerhild Becker

Recruiting

Protreat-Trial: Prophylactic Antiemetic Treatment of Opioid-induced Nausea and Vomiting (OINV) in Palliative Care (ProTreat)

Pain | Nausea | Vomiting | Advanced Cancer

Germany

Search clinical trials for: Romosozumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations